Therefore, the prognosis of lung cancer patients might be determined by their responses to chemo-/radiotherapy and might be associated with stem-like phenotype/MITF-low expression [59], whereas melanoma patients’ prognosis might be determined largely by tumor growth and might be associated with differentiated state/MITF-high expression. This evidence concerns the gene MITF and lung carcinoma.